donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
GSK GlaxoSmithKline
43.750
+0.220+0.51%
Post Mkt Price
43.710
-0.04-0.09%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Total revenue
31.84% 9.78B 0.04% 34.11B 9.02% 9.53B 4.98% 9.08B
Operating revenue
31.84% 9.78B 0.04% 34.11B 9.02% 9.53B 4.98% 9.08B
Cost of revenue
48.79% 3.69B -0.86% 11.6B 16.05% 3.68B 0.14% 2.89B
Gross profit
23.33% 6.09B 0.52% 22.51B 5.01% 5.85B 7.41% 6.19B
Operating expense
1.36% 3.29B -2.12% 15.83B 9.87% 4.95B 8.89% 4.25B
Selling and administrative expenses
17.18% 2.84B -4.2% 10.98B 3.1% 3.26B -0.86% 2.65B
-General and administrative expense
17.18% 2.84B -4.2% 10.98B 3.1% 3.26B -0.86% 2.65B
Research and development costs
4.38% 1.17B 3.53% 5.28B -1.5% 1.45B 30.7% 1.49B
Other operating expenses
-- -- -- -- -- 379M 28.49% 230M
Operating profit
65.45% 2.8B 7.37% 6.68B -15.65% 895M 4.31% 1.94B
Net non-operating interest income expense
-5.76% -202M 11.29% -754M 20.09% -187M 2.53% -193M
Non-operating interest income
0% 10M -10.34% 26M -20% 4M -- 7M
Non-operating interest expense
5.47% 212M -9.23% 777M -20.08% 191M 1.01% 200M
Total other finance cost
-- -- -86.96% 3M -- -- -- --
Other net income (expense)
Special income (charges)
-- -- -91.55% 96M -- -- -- --
-Less:Restructuring and merger&acquisition
-- -- -17.73% 1.06B -- -- -- --
-Less:Other special charges
-- -- 52.35% -1.15B -- -- -- --
Income before tax
71.15% 2.6B -21.9% 5.44B -14.01% 706M 4.61% 1.75B
Income tax
67.05% 431M -40.34% 346M -1144.44% -224M 57.68% 380M
Net income
71.98% 2.17B -20.23% 5.1B 10.85% 930M -4.34% 1.37B
Net income continuous Operations
71.98% 2.17B -20.23% 5.1B 10.85% 930M -4.34% 1.37B
Minority interest income
95.19% 365M 11.27% 711M 11.73% 181M 7.53% 200M
Net income attributable to the parent company
67.94% 1.8B -23.73% 4.39B 10.64% 749M -6.11% 1.17B
Preferred stock dividends
Other preferred stock dividends
0 0 0 0
Net income attributable to common stockholders
67.94% 1.8B -23.73% 4.39B 10.64% 749M -6.11% 1.17B
Basic earnings per share
66.98% 0.718 -24.16% 1.752 10.29% 0.3 -6.8% 0.466
Diluted earnings per share
67.14% 0.712 -24.1% 1.732 9.7% 0.294 -6.48% 0.462
Dividend per share
-1.31% 0.4513 0.72% 1.5928 0.16% 0.3882 1.92% 0.3762
Currency Unit
GBPGBPGBPGBP
Accounting Standards
NonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAP

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; CEPI; Innovax and Xiamen University; VBI; and Viome. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
CEO: Walmsley, Emma N.
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...